Your heart is in the right place
Learn more about advances in care and treatment for patients at The Ohio State University Heart and Vascular Center
Expert care starts hereThere’s a powerful story behind every headline at Ohio State Health & Discovery. As one of the largest academic health centers and health sciences campuses in the nation, we are uniquely positioned with renowned experts covering all aspects of health, wellness, science, research and education. Ohio State Health & Discovery brings this expertise together to deliver today’s most important health news and the deeper story behind the most powerful topics that affect the health of people, animals, society and the world. Like the science and discovery news you find here? You can support more innovations fueling advances across medicine, science, health and wellness by giving today.
Subscribe. The latest from Ohio State Health & Discovery delivered right to your inbox.
SubscribeObesity now affects 1 in 3 Americans. With current trends, this could reach 1 in 2 by 2035.
It’s no surprise that new forms of injectable weight loss medications (a category called GLP1 receptor agonists) have soared in use.
Aside from a smaller waist size, these medications lead to other life-changing effects. The biggest benefit? A decrease in death from heart disease — the leading killer of Americans.
The GLP1-RA drugs (e.g., semaglutide, liraglutide) are injected under the skin. They act like certain gut hormones that promote a feeling of fullness after a meal and slow stomach-emptying, thereby curbing appetite.
These drugs also encourage the pancreas to release additional insulin when you eat and stop the liver from making extra glucose, the key sugar found in the bloodstream.
So, your blood sugar levels lower and your stomach digests food more slowly, which leaves you feeling fuller even after eating less food.
The drug maker that produces Wegovy and Ozempic supported a study showing these drugs can lower the risk of heart attack, stroke and death from heart disease by 20% in overweight or obese adults who don’t have diabetes.
Blood sugar reduction is presumed to be helpful when it comes to heart attack and stroke risk, but only certain diabetes drugs have proven cardiovascular and/or weight loss benefits; in fact, other drugs have shown potential harm.
Insulin therapy is necessary for many people with type 2 diabetes, yet it can lead to weight gain. The amount of weight loss itself isn’t likely enough to account for the degree of heart risk reduction that was observed in the trial.
Reasons for the benefit could include decreases in inflammation, salt retention and blood pressure, all of which can promote healthy effects in the heart and blood vessels. Some early studies also suggest that people treated with semaglutide and tirzepatide could have a reduced tendency to drink alcohol excessively.
Before concluding that semaglutide and similar medications are “wonder drugs,” let’s note that side effects can be significant. In many people, they lead to satiety (“feeling full”), but others can experience significant nausea, vomiting or diarrhea. Some people have concerns about the ability to sustain the reduced weight after stopping the drugs.
Notably, the heart and vascular benefits of semaglutide can’t be translated to other weight loss drugs, such as stimulants (e.g., phentermine). If you’re interested in losing weight, talk to your doctor about an individualized approach.
The goal is to:
Regardless of whether you take weight loss injections, if you work to do the following, it could mean better heart health for you:
Learn more about advances in care and treatment for patients at The Ohio State University Heart and Vascular Center
Expert care starts here